Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 128,578

Document Document Title
WO/2017/218905A1
Described herein are methods and compositions for the use of treating Spinal Muscular Atrophy (SMA). Aspects of the invention relate to administering to a subject in need thereof an agent that inhibits muscarinic acetylcholine receptor. ...  
WO/2017/214725A1
A method of screening a compound or a composition for use in modulating opioid withdrawal symptoms in a mammal. The method comprises the steps of: selecting a group of test animals; separating the group into two subgroups; inducing panne...  
WO/2017/218519A1
The invention provides, in part, compositions and methods for treating neuronal ceroid lipofuscinoses (NCL). The invention further provides, in part, gene therapy compositions and methods for the treatment, prevention, or amelioration of...  
WO/2017/216362A1
Described are methods for producing cannabinoid prodrugs using enzyme-catalysed synthesis / chemical modifications as well as methods for formulating such prodrugs in a pharmaceutically acceptable form and their use as therapeutic agents...  
WO/2017/216792A1
Compounds represented by Formula I are disclosed herein, wherein R, Ra and R1-R14 are as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease...  
WO/2017/215636A1
Provided are a diaryl sulphide piperazine compound and a preparation method and a use thereof. In particular, the compound is a compound shown by formula (I), wherein HX is a C10-20 fatty acid or pamoic acid.  
WO/2017/216771A3
Methods and systems for targeted genomic modification within a target genome region (TGR) in a mammalian cell. In particular, there is provided a CRISPR/Cas9 system comprising: one or more guide RNA (gRNA) comprising a CRISPR RNA (crRNA)...  
WO/2017/218518A1
Compositions and methods for treatment of acute and chronic pain are disclosed herein. These compositions include fixed dose oral formulations containing an atypical antipsychotic drug and an opioid. Also provided here are methods of tre...  
WO/2017/215722A1
The invention relates to a composition for treating or preventing the development of emotion and/or mood disorders in a human individual, such as anxiety or depression. The human is a patient having obesity coupled with a metabolic risk ...  
WO/2017/218815A1
Disclosed herein are methods and compounds for treating a motor-associated neurodegenerative disease or condition. In some instances, also included herein are methods and compounds for treating a TDP-43 associated neurodegenerative disea...  
WO/2017/218950A1
The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease o...  
WO/2017/215600A1
Provided are a substituted tricyclic herteocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical compo...  
WO/2017/218963A1
Methods and pharmaceutical compositions for use in treating diseases associated with insufficient activity of the pantothenate kinase enzyme (e.g., CASTOR diseases) are disclosed. The methods and compositions involve an effective amount ...  
WO/2017/217545A1
The present invention provides a plexin binding regulator comprising a cyclic peptide having an Arg-Trp-Thr structure or a Leu-Ser-Trp structure or a pharmaceutically acceptable salt thereof.  
WO/2017/214940A1
A lentiviral expression vector for specifically promoting high expression of a Cplx2 gene comprises a fundamental sequence, a resistance gene sequence, a multiple-cloning-sites sequence, a promoter sequence, and a Cplx2 gene cDNA sequenc...  
WO/2017/216661A1
The present invention relates to a process for the preparation of 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy} quinolin-2(1H)-one (brexpiprazole) from 7-(4-chlorobutoxy)quinolin-2(1H)-one and 1-(benzo[b]thiophen-4-yl)piperazine. ...  
WO/2017/216813A1
The invention relates to a composition to reduce DNA and hepatic damage and to enhance repair thereof. More particularly the invention relates to a synergistic composition comprising combination of active ingredients which can be used in...  
WO/2017/215602A1
Provided in the present invention is a use of doxycycline in the preparation of a medicine for treating or preventing aging diseases, wherein the doxycycline is administered at a dose of less than 2 μg/ml, and the aging diseases mainly ...  
WO/2017/218632A1
The invention relates to devices and methods for detecting the presence of antibodies to folic acid in a sample.  
WO/2017/216771A2
Methods and systems for targeted genomic modification within a target genome region (TGR) in a mammalian cell. In particular, there is provided a CRISPR/Cas9 system comprising: one or more guide RNA (gRNA) comprising a CRISPR RNA (crRNA)...  
WO/2017/217556A1
The purpose of the present invention is to provide a medicine for preventing or treating TGFβ-related diseases by inhibiting signal transduction of TGFβ. Provided are: a TGFβ inhibitor that contains, as an active ingredient, the REIC/...  
WO/2017/218843A1
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof. (Formu...  
WO/2017/218681A1
The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symp...  
WO/2017/215591A1
Methods for treating central nervous system (CNS) disorders or attenuating pain with a lithium benzoate compound.  
WO/2017/212420A1
The present disclosure relates to methods and compositions for managing neuroinflammation and neuroinflammation mediated neurodegenerative disease or disorder.  
WO/2017/212414A1
Compounds of Formula (I) able to modulate Store Operated Calcium Entry (SOCE). The disclosure also relates to the use of compounds of formula (I) for treatment of pathological conditions in which SOCE modulation might be beneficial, such...  
WO/2017/214286A1
Disclosed are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and pharmaceutical compositions for treating a subject in need thereof. The disclosed compounds may be described as substit...  
WO/2017/211274A1
Provided are the use of lipids bearing fatty acids with an odd number of carbon atoms as pharmaceuticals or nutritional supplement. In particular, such lipids are used in the treatment and/or prevention of neurodegenerative diseases, opt...  
WO/2017/213490A1
The invention pertains totheuse of therapeutically effective amounts of (i) vitamin A and/or functional equivalents, (ii) vitamin D and/or functional equivalents, and (iii) at least one omega-3 PUFA, preferably DHA and/or EPA, more prefe...  
WO/2017/212329A1
This invention relates to proteolysis targeting chimeric molecules formed from the intracellular self-assembly of precursors via bioorthogonal click chemistry (CLIPTACs), as well as related precursor compositions, methods and therapeutic...  
WO/2017/213176A1
[Problem] To provide a food or beverage composition, a food or beverage and the like which include astaxanthin and/or an astaxanthin-containing extract as an active ingredient. [Solution] A food or beverage composition which includes ast...  
WO/2017/213208A1
The present invention relates to a sustained-release preparation composition that is intended to be applied to animals. The preparation composition contains a medicinal agent, a sugar, a wax and a water-soluble polymer.  
WO/2017/213504A1
The invention pertains to the use of therapeutically effective amounts of (i) vitamin A and/or functional equivalents, (ii) vitamin D and/or functional equivalents, and (iii) at least one omega-3 PUFA, preferably DHA and/or EPA, more pre...  
WO/2017/213524A1
Pharmaceutical compositions and methods for the treatment of subjects who have, or are at risk for, Alzheimer's disease. The composition comprises triethylenetetramine succinate compounds, alone or in combination with agents to reduce th...  
WO/2017/211307A1
The present invention relates to a benzene derivative, and a manufacturing method and pharmaceutical application thereof. The invention specifically relates to a benzene derivative as represented by formula (A), or a stereoisomer, solvat...  
WO/2017/211248A1
Disclosed are a substituted imidazoquinazoline compound as represented by formula (I), and a pharmaceutical composition containing its crystalline form, pharmaceutically acceptable salt, prodrug, stereoisomer, isotopic variant, hydrate, ...  
WO/2017/214005A1
The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicament.  
WO/2017/214538A1
Pharmaceutical compositions are provided, which comprise effective amounts of an opioid analgesic such as oxycodone, and an antiemetic, such as promethazine, to treat a subject for conditions, including for reducing or eliminating an adv...  
WO/2017/210839A1
A calming herbal wine formulation with Fructus Schisandrae, prepared using the following ingredients provided in the respective amounts: 15-20 g of Fructus Schisandrae; 15-20 g of Rhizoma Acori Graminei; 8-15 g of Semen Ziziphi Spinosa; ...  
WO/2017/214505A1
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the en...  
WO/2017/212113A1
The present invention relates to a composition for preventing and/or diminishing the symptoms of hangover caused by alcohol consumption in humans. The invention relates also to use of the composition for preventing and/or diminishing the...  
WO/2017/206096A1
Provided is an agomelatine soft capsule preparation, wherein the agomelatine soft capsule preparation is composed of a liquid composition and a soft capsule shell; the liquid composition is sealed inside the soft capsule shell; the liqui...  
WO/2017/209106A1
The present invention provides a novel oral composition of a single or twice daily dose type, which contains tipepidine or a pharmaceutically acceptable salt thereof, wherein the drug dissolution rate of tipepidine or the pharmaceuticall...  
WO/2017/209156A1
To provide a novel brain function improving agent. Provided is a brain function improving agent that comprises, as an active ingredient, Bifidobacterium breve and/or a culture containing Bifidobacterium breve.  
WO/2017/208868A1
The purpose of the present invention is to provide a pharmaceutical composition and a food which have the effect of preventing central nervous system diseases and inhibiting the advancement thereof. This pharmaceutical composition, which...  
WO/2017/208172A1
The present invention relates to a composition for use as a medicament, in the form of a gel with characteristics of a reversible thermogel, based on one or more poloxamers, water and optionally excipients, and an effective amount of an ...  
WO/2017/208072A3
Cannabinoid containing pharmaceutical compositions suitable for nasal administration are disclosed. The compositions comprise the aforementioned cannabinoids and excipients selected such that the compositions are semi-solid or viscous li...  
WO/2017/210278A1
Disclosed herein are anti-RGMa antibodies and methods of using these antibodies to treat spinal cord injury, including promoting axonal regeneration, functional recovery, or both and to treat pain, including neuropathic pain arising from...  
WO/2017/208869A1
The purpose of the present invention is to provide a pharmaceutical composition and a food which have the effect of preventing central nervous system diseases and inhibiting the advancement thereof. This pharmaceutical composition is use...  
WO/2017/208251A1
The present invention relates to a new crystalline polymorph of brexpiprazole. More specifically, the invention relates to novel Form M of brexpiprazole, process for preparing the novel form of brexpiprazole and pharmaceutical formulatio...  

Matches 351 - 400 out of 128,578